Table 5.

Other sensitivity analyses (€/QALY)

Scenario	Denosumab vs. no treatment	Denosumab vs. generic alendronate	Denosumab vs. risedronate	Denosumab vs. strontium ranelate
Base–casea	9,250	20,976	6,998	710
Discount rates (5%)	9,576	22,622	6,868	133
Discount rates (0%)	9,414	19,285	7,793	2,139
One year DAPS persistence	10,656	28,501	8,548	214
Perfect persistence for all treatments	6,902	58,449	6,817	Cost saving
Denosumab maximum offset time 2 years	14,157	33,103	14,254	6,278
All treatments maximum offset time 2 years	14,157	27,970	11,897	5,127
10-year modelling horizon	5,484	22,422	1,454	Cost saving
GIAEsb for alendronate/risedronate		20,976	6,998	–
Disutility from fractures decreased by 10%	9,819	22,256	7,426	755
20% of excess mortality attributable to fractures	4,886	18,231	2,267	Cost saving
10 year treatment duration	8,758	21,455	6,457	Cost saving
Mortality after hip and vertebral fractures 3 years	6,084	18,780	3,475	Cost saving
Mortality after hip and vertebral fractures 5 years	8,157	20,182	5,766	Cost saving

^aThe base case assumed discount rates of 3%, improved persistence for 3 years, max offset time of 5 years for all treatments, life-time horizon, no adverse events for any treatment, 5-year maximum treatment duration, 8 years of increased post-fracture mortality after hip and vertebral fractures

^bGastrointestinal adverse events